Join the Oncology Voice Network. Join for Free
From Data Disseminator to Trusted Advisor
Medical Science Liaisons MSL team strategies Key Opinion Leader engagement MSL value measurement trusted advisor role

From Data Disseminator to Trusted Advisor


Share This Article


Summary

In this episode, Chad Fellers shares insights from his experience as an MSL, highlighting his team's success strategies during COVID-19. He discusses the evolving role of MSLs as trusted advisors and offers advice on how to measure and enhance MSL value. Chad explores the future of Key Opinion Leader (KOL) engagement and the influence of digital platforms, as well as adjustments in travel and administrative duties. He emphasizes the importance of active listening and provides tips for MSLs to build strong advisor relationships. The episode also touches on Chad's personal interests, including streaming favorites and dietary changes influenced by documentaries.

Learn about how MSLs go from data disseminators to trusted advisors in my conversation with Chad Fellers, Director of Medical Science Liasons at Harmony Biosciences.  

In this episode we discuss: 

  • The success of his team despite COVID. 

  • The unique approach their team uses in engaging their KOLs. 

  • Measuring and assessing value from an MSL perspective. 

  • His stance in leading his MSL team. 

  • The future of KOL engagement for MSLs. 

  • Effect of the change of less travel to MSLs. 

  • How it’s going to look like as things open up. 

  • Advice for MSLs to stay focused, on track, and continue to be a trusted advisor.

Click for Source
Medical Science Liaisons, MSL team strategies, Key Opinion Leader engagement, MSL value measurement, trusted advisor role

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Explore OVN